Enliven Therapeutics Inc. (NASDAQ:ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.The clinical-stage biopharmaceutical company shared encouraging initial data from the ongoing Phase 1b ENABLE trial of ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs).DataAs of the cutoff date of December 22, 2025, 60 ...

Core Insights - Novartis will present over 70 abstracts at the upcoming ASH and SABCS meetings, highlighting advancements in hematology and oncology, including 11 oral presentations and a late-breaker abstract for the Phase III VAYHIT2 trial of ianalumab in immune thrombocytopenia (ITP) [1][2][3] Hematology Highlights - The pivotal Phase III trial results for ianalumab in ITP patients previously treated with corticosteroids will be presented as a late-breaker [3] - Scemblix (asciminib) shows continued improvement in patient-reported outcomes compared to investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia (CML) [2][3] - The 96-week data from the Phase III MANIFEST-2 study of pelabresib plus ruxolitinib in myelofibrosis represents the longest follow-up in a randomized combination trial [3] Oncology Highlights - Kisqali (ribociclib) data from the MONALEESA studies indicate long-term benefits for early and metastatic breast cancer patients [3] - The pooled analysis of patients treated with first-line ribociclib plus endocrine therapy shows long-term progression-free survival [5] - Five-year analysis of distant disease-free survival from the NATALEE trial of ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer patients will be presented [5] Product Information - Novartis has a strong legacy in hematology, having delivered over 10 medicines for more than 15 blood cancers and serious blood disorders over the past two decades [7][8] - The company has been at the forefront of scientific advancements in breast cancer for over 30 years, leading in the discovery of new therapies and combinations [9]

Core Viewpoint - Terns Pharmaceuticals Inc. is experiencing a significant increase in stock price following positive data from the ongoing CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML), suggesting the potential for TERN-701 to be a transformative therapy in the CML treatment landscape [1][2][3]. Group 1: Trial Data and Efficacy - The CARDINAL trial is currently in the dose-escalation and dose-expansion phases, with 55 patients enrolled as of June 30 [2]. - Among 32 efficacy-evaluable patients, the major molecular response (MMR) achievement rate at 24 weeks is reported at 64%, which is significantly higher than rates in other Phase 1 studies of CML therapies [2][3]. - The overall cumulative MMR rate is 75% (24 out of 32 patients), with 100% (10 out of 10) maintaining MMR [6]. Group 2: Market Reaction and Analyst Sentiment - TERN stock has surged by 88.67%, reaching $15.58 [4]. - William Blair has upgraded Terns to Outperform from Market Perform, highlighting the promising outcomes of the TERN-701 readout [3]. - Analyst Andy Hsieh believes that TERN-701 has the potential to significantly disrupt the current CML treatment market, which is dominated by Novartis AG's Scemblix [3].